Effect of hormone replacement therapy with femoston on hemostasis in peri- and postmenopausal women

Medical Science Monitor

Volumn 8, Issue 9, 2002, Pages

  Repina, Margarita A ^a   Korzo, Tatyana M ^a   Zinina, Tatyana A ^a  

^a NONE   (Russian Federation)

Author keywords

17 estradiol; Blood coagulation; Dydrogesterone; Hemostasis; Lipoproteins; Platelets

Indexed keywords

BLOOD CLOTTING FACTOR; DYDROGESTERONE PLUS ESTRADIOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN;

ADULT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; MENSTRUATION; POSTMENOPAUSE;

ADULT; APOPROTEINS; CLIMACTERIC; DRUG COMBINATIONS; DYDROGESTERONE; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HEMOSTASIS; HORMONE REPLACEMENT THERAPY; HUMANS; LIPOPROTEINS; LUTEINIZING HORMONE; MENSTRUATION; MIDDLE AGED; POSTMENOPAUSE; TIME FACTORS;

EID: 18244414553     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Gensini GF, Micheli S, Abbate R: Risk factors for cardiac diseases in women. In: Dalla Volta S, Bayés cie Luna A, Brochier M, Dienstl F, Jezck V, Mortensen SA, Poole-Wilson PA, editors. Cardiology. 1st ed. Berkshire, England: McGraw-Hill International, 1999; 799-806
2. Kharitonov SA, Logan-Sinclar RB, Busset CM, Shinebourne EA: Peak expiratory nitric oxide differences in men and women: relation to the menstrual cycle. Br Heart J, 1994; 79: 243-5
3. Polderman KH, Stehouwer CD, Van Kamp GJ et al: Influence of -sex hormones on plasma endothelin levels. Ann Intern Med, 1993; 118: 429-232
4. Gilligan DM, Badar DM, Panza JA et al: Acute vascular effects of estrogen in postmenopausal women. Circulation, 1994; 90: 786-791
5. Collins P, Shay, J, Jiand C, Moss J: Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation, 1994; 90: 1964-68
6. Finucane FF, Madans JH, Bush TL et al: Decreased risk of stroke among postmenopausal hormone users. Results from it national cohort. Arch Intern Med, 1993; 153: 73-9
7. Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P: Beneficial effects of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993; 342: 133-6.
8. Mosca L, Manson JE, Sutherland SE et al: Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation, 1997; 96: 2468-82
9. Repina MA: The role of postmenopausal disorder correction. In: Actual problems of therapy and rehabilitation in elderly patients. St Petersburg, 1996; 43-44
10. Haarbo J, Hansen BF, Christiansen C: Hormone replacement therapy prevents coronary artery disease in ovariectomized cholesterolfed rabbits. APMIS, 1991; 99: 721-7
11. Nabulsi AA, Folsom AR, White A et al: Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. New Engl J Med, 1993; 328: 1069-75
12. Lane G, Siddle NC, Ryder TA et al: Effects of dydrogesterone on the oestrogenized postmenopausal endometrium. Br J Obst Gynaecol, 1986; 93: 55-62
13. Lane G, Siddle NC, Ryder TA et al: Endometrial responses, side effects and bleeding responses in postmenopausal women using various doses of dydrogesterone in combination with conjugated estrogens. Br J Clin Pract, 1983; 24: 23-26
14. Siddle NC, Fraser D, Whitehead MI et al: Endometrial, physical and psychological effects of postmenopausal estrogen therapy with added dydrogesterone. Br J Obstet Gynaecol, 1990; 97: 1101-1107
15. Rees M, Leather A, Pryse-Davies J et al: A first study to compare two dosages of dydrogesterone in opposing the 50 mg estradiol implant. Maturitas, 1991; 14: 9-15
16. Lacey RW, Howson G, Samson GA: Safety of progestins: effects of dydrogesterone in blood lipids. Br J Clin Pract, 1983; 24: 2-10
17. Crook D, Godsland IF, Hull J, Stevenson JC: Hormone replacement therapy with dydrogesterone and 17b-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 months follow up. Br J Obstet Gynaecol, 1997; 104: 298-304
18. Hänggi W, Lippuner K, Riesen W et al: Long term influence of different postmenopausal hormone replacement regiments on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol, 1997; 104: 708-717
19. Mijatovic V, van der Mooren MJ, Stchouwer CDA et al: Review. Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Gynet Endocrinol, 1999; 13: 130-144
20. Rozenbaum H: Progestins and endometrial safety: the French point of view. Drugs Today, 1996; 32: 15-23
21. Crook D: Postmenopausal hormone replacement therapy, lipoprotein metabolism and coronary heart disease. J Cardiovasc Pharmacol, 1996; 28: 40-45
22. Campaguoli C, Belforte P, Di Sario MM, Lesca L: Lipid profile during hormone replacement therapy: effect of different progestins? Zeutralbl Gynakol, 1997; 119: 1-6
23. Pickar JH, Thorneycroft I, Whitehead M: Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995. Am J Obstet Gynecol, 1998; 178: 1087-1099
24. Gökmen O, Yapar Eyi EG: Hormone replacement therapy and lipid-lipoprotein concentrations. Eur J Obstet Gynec Reprod Biol, 1999; 85: 31-41
25. Vermylen J, Verstraete M, Brosens I: Effect of dydrogesterone (Duphaston) on haemostasis and liver function. J Obstet Gynaecol Br Cwhh, 1973; 80: 75-81
26. Winkler UH, Lanck US, Ebert Ch, Schindler AE: Der Eiufluß zyklisch verabreichter Gestagene auf die plasmatischen Gerinnungsfaktoren. Zentralblatt für Gynäkologie, 1998; 120: 32-37
27. Van der Mooren MJ, Demacker PNM, Thomas CMG et al: A 2 year study on the beneficial effects of 17b-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavorable effects of dydrogesterone. Euro J Obstet, Gynecol Resprod Biol, 1993; 52: 117-123
28. Meijer S, Büller HR, de Boer K et al: Coagulation status in post-menopausal women using 17b-oestradiol and dydrogesterone. Thromb. Haemostasis, 1993; 69: 629
29. Crook D: Multicentre evaluation of 17(estradiol and dydrogesterone HRT on cardiovascular risk [abstract no. F200]. 8th International Congress on Menopause, Sydney, Australia, 1996; 106
30. L'Hermite M: Sex hormones and cardiovascular risk. Acta Cardiologica, 1991; 46: 357-372
31. Godsland IF, Gangar K, Walton C et al: Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabol Clin Exp, 1993; 42: 846-853
32. Gaspard UJ, Gottal JM, van den Brile FA: Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas, 1995; 21: 171-178
33. Stevenson JC: The metabolic and cardiovascular consequences of HRT. Br J Clinical Pract, 1995; 49: 87-90
34. Caudron J, Hendrickx B: Comparison of two equine estrogen dydrogesterone regimens in the climacteric. Maturitas. 1988; 10: 133-141
35. Van der Mooren MJ, Hanselaar AGJM, Borm GF, Rolland R: Changes in the withdrawal bleeding pattern and endometrial histology during 17b-estradiol-dydrogesterone therapy in postmenopausal women. A 2 year prospective study. Maturitas, 1995; 20: 175-180
36. Gaspard UJ, Wery OJ, Scheen AJ et al: Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women. Climacteric, 1999; 2: 93-100
37. De Cleyn K, Buytaert P, Delbeke L, Gerris J: Equine estrogen dydrogesterone therapy in the management of postmenopausal women. Eur J Obstet, Gynecol Reprod Biol, 1986; 23: 2011-209